Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06255392

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions Fludzoparib" and Anti-angiogenic HRD-positive/HER2-negative Advanced Breast Cancer

Interventions Apatinib Mesylate Capecitabine tablets Eribulin mesylate injection Fluzoparib Gemcitabine Hydrochloride Paclitaxel-albumin Vinorelbine Tartrate Oral

Updated 4 times since 2024 Last updated: Aug 12, 2025 Started: Jun 12, 2024 Primary completion: Mar 31, 2031 Completion: Mar 31, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06255392, this PHASE3 trial focuses on Fludzoparib" and Anti-angiogenic and HRD-positive/HER2-negative Advanced Breast Cancer and remains actively recruiting participants. Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, it has been updated 4 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Mar 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Data source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China